

On page 25, lines 9-10, after "*t*-boc-NHOCH₂CO-Gly₃-[Lys(*t*-Boc-Ser(Bzl))]₅-Gly-OCH₂-PAM", please insert --(SEQ. ID. No. 5)--.

In the Claims:

Please amend claims 14, 16, 19, 21, 26, and 28 as follows:

A1
14. (Amended) A compound according to claim 13, wherein the pentapeptide is -Gly-Ala-Leu-Gly-Leu- (SEQ. ID. No. 2).

A2
16. (Amended) A compound according to claim 15, wherein the tetrapeptide is -Leu-Ala-Leu-Ala- (SEQ. ID. No. 1).

A3
19. (Amended) A method according to claim 18, wherein the pentapeptide is -Gly-Ala-Leu-Gly-Leu- (SEQ. ID. No. 2).

A4
21. (Amended) A method according to claim 20, wherein the tetrapeptide is -Leu-Ala-Leu-Ala- (SEQ. ID. No. 1).

A5
26. (Amended) A method according to claim 25, wherein the pentapeptide is -Gly-Ala-Leu-Gly-Leu- (SEQ. ID. No. 2).

A6
28. (Amended) A method according to claim 27, wherein the tetrapeptide is -Leu-Ala-Leu-Ala- (SEQ. ID. No. 1).

REMARKS

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.

The objection to the specification for failure to comply with the sequence rules 37 CFR §§ 1.821-1.825 is respectfully traversed in view of the above amendments.

In response to the written restriction requirement, applicants hereby elect the invention of Group I (claims 1 to 11, drawn to betulinol derivatives), with traverse.